Heron shares surge on positive pain drug data

Shares of Redwood City, CA-based Heron Therapeutics shot up 20% on its release of positive data from its Phase II clinical study of HTX-011 for treating post-operative pain in patients undergoing bunionectomy. The biotech says that all primary and secondary endpoints were met in the study of their drug, a long-acting formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam. Release

Suggested Articles

The action will see Kiadis switch its attention to earlier-stage natural killer cell therapies against solid tumors and hematological cancers.

The Weill Family Foundation is stumping up $106 million to create a so-called “Neurohub.”

The takeover centers on TRPML1 agonists designed to treat neurodegenerative disorders by clearing toxic proteins from the brain.